References 585 & 563. Shrime MG, Goldstein DP, Seaberg RM, Sawka AM, Rotstein L, Freeman JL, et al. Cost-effective management of lowrisk papillary thyroid carcinoma. Archives of otolaryngology - head & neck surgery. 2007;133:1245-1253. https://doi. org/10.1001/archotol.133.12.1245. 564. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery. 2001;130:921-930. https://doi.org/10.1067/msy.2001.118370. 565. Neudeck MR, Steinert H, Moergeli H, Weidt S, Seiler A, Strobel K, et al. Work ability and return to work in thyroid cancer patients and their partners: a pilot study. Psychooncology. 2017;26:556-559. https://doi.org/10.1002/ pon.4154. 566. Ketterl TG, Syrjala KL, Casillas J, Jacobs LA, Palmer SC, McCabe MS, et al. Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors. Cancer. 2019;125:1908-1917. https:// doi.org/10.1002/cncr.31985. 567. Leso V, Vetrani I, De Cicco L, Cardelia A, Fontana L, Buonocore G, et al. The Impact of Thyroid Diseases on the Working Life of Patients: A Systematic Review. Int J Environ Res Public Health. 2020;17. https://doi.org/10.3390/ ijerph17124295. 568. Waissi F, Kist JW, Lodewijk L, de Wit AG, van der Hage JA, van Dalen T, et al. Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial). Clinical nuclear medicine. 2019;44:272-275. https://doi.org/10.1097/RLU.0000000000002420. 569. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. European journal of endocrinology. 2007;156:531-538. https://doi.org/10.1530/EJE-06-0724. 570. Emmanouilidis N, Schrem H, Winkler M, Klempnauer J, Scheumann GF. Long-term results after treatment of very low-, low-, and high-risk thyroid cancers in a combined setting of thyroidectomy and radio ablation therapy in euthyroidism. Int J Endocrinol. 2013;2013:769473. https://doi.org/10.1155/2013/769473. 571. Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15:1147-1155. https://doi.org/10.1089/ thy.2005.15.1147. 572. Nijhuis TF, van Weperen W, de Klerk JMH. Kosten samenhangend met de onttrekking van schildklierhormoontherapie bij de follow-up van het gedifferentieerde schildkliercarcinoom. Tijdschr Nucl Geneeskd. 1999;21:98-100. 573. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613-619. https://doi.org/10.1089/thy.1997.7.613. 574. Park JH, Park EC, Park JH, Kim SG, Lee SY. Job loss and re-employment of cancer patients in Korean employees: a nationwide retrospective cohort study. Journal of clinical oncology. 2008;26:1302-1309. https://doi.org/10.1200/ JCO.2007.14.2984. 575. Tamminga SJ, Bultmann U, Husson O, Kuijpens JL, Frings-Dresen MH, de Boer AG. Employment and insurance outcomes and factors associated with employment among long-term thyroid cancer survivors: a population-based study from the PROFILES registry. Quality of life research. 2016;25:997-1005. https://doi.org/10.1007/s11136-0151135-z. 576. van Buuren S. Flexible Imputation of Missing Data. Second Edition. Boca Raton, FL, USA: CRC Press; 2018. 577. Olvera Astivia OL, Zumbo BD. Heteroskedasticity in Multiple Regression Analysis: What it is, How to Detect it and How to Solve it with Applications in R and SPSS. Practical Assessment, Research, and Evaluation. 2019;24. https:// doi.org/10.7275/q5xr-fr95. 578. Pomp M, Brouwer W, Rutten F. QALY-time: New medical Technology, cost-effectiveness and guidelines [“QALY-tijd: Nieuwe medische technologie, kosteneffectiviteit en richtlijnen”] (CPB Document 152). 2007. 579. Hu QL, Schumm MA, Zanocco KA, Yeh MW, Livhits MJ, Wu JX. Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodules. Surgery. 2022;171:147-154. https://doi.org/10.1016/j.surg.2021.04.050. 580. Schumm MA, Nguyen DT, Kim J, Tseng CH, Chow AY, Shen N, et al. Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules. Annals of surgical oncology. 2021;28:8872–8881. https://doi.org/10.1245/s10434-021-10375-6. 581. Bernet VJ, Chindris AM. Update on the Evaluation of Thyroid Nodules. Journal of nuclear medicine. 2021;62:13S-19S. https://doi.org/10.2967/jnumed.120.246025. 582. Applewhite MK, James BC, Kaplan SP, Angelos P, Kaplan EL, Grogan RH, et al. Quality of Life in Thyroid Cancer is Similar to That of Other Cancers with Worse Survival. World journal of surgery. 2016;40:551-561. https://doi. org/10.1007/s00268-015-3300-5. 583. Bianchi GP, Zaccheroni V, Solaroli E, Vescini F, Cerutti R, Zoli M, et al. Health-related quality of life in patients with thyroid disorders. Quality of life research. 2004;13:45-54. https://doi.org/10.1023/B:QURE.0000015315.35184.66.
RkJQdWJsaXNoZXIy MTk4NDMw